Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAPDH | P04406 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615384 | 0.92 | RIPK1 (0.35) | RIPK1TNK2 | |
| SCHEMBL24791260 | 0.90 | ALDH1A1 (0.36) | ALDH1A1MAPTRIPK1MEN1USP2 | |
| SCHEMBL14996153 | 0.90 | ALDH1A1 (0.36) | ALDH1A1MAPTRIPK1MEN1USP2 | |
| SCHEMBL881372 | 0.90 | ALDH1A1 (0.36) | ALDH1A1MAPTRIPK1MEN1USP2 | |
| SCHEMBL10171966 | 0.89 | ALDH1A1 (0.36) | ALDH1A1MAPTRIPK1MEN1USP2 | |
| SCHEMBL17129843 | 0.88 | MAPT (0.35) | ALDH1A1MAPTRIPK1MEN1USP2 | |
| SCHEMBL16480683 | 0.85 | POLB (0.35) | ALDH1A1MAPTRIPK1MEN1USP2 | |
| SCHEMBL25914985 | 0.84 | ALDH1A1 (0.38) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL18697905 | 0.84 | ALDH1A1 (0.38) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL24168927 | 0.84 | ALDH1A1 (0.35) | ALDH1A1RIPK1MEN1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | ALDH1A1 1085/4885MAPT 450/4885RIPK1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.